Compare MIDD & PTCT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | MIDD | PTCT |
|---|---|---|
| Founded | 1888 | 1998 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Industrial Machinery/Components | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 6.1B | 5.7B |
| IPO Year | 1995 | 2006 |
| Metric | MIDD | PTCT |
|---|---|---|
| Price | $138.78 | $69.10 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 8 | 17 |
| Target Price | ★ $180.13 | $80.65 |
| AVG Volume (30 Days) | 506.4K | ★ 1.4M |
| Earning Date | 05-08-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 264.48 |
| EPS | N/A | ★ 0.90 |
| Revenue | ★ $3,201,202,000.00 | $264,734,000.00 |
| Revenue This Year | $5.87 | N/A |
| Revenue Next Year | $3.22 | $17.70 |
| P/E Ratio | ★ N/A | $75.68 |
| Revenue Growth | N/A | ★ 36.19 |
| 52 Week Low | $110.82 | $43.18 |
| 52 Week High | $180.13 | $90.87 |
| Indicator | MIDD | PTCT |
|---|---|---|
| Relative Strength Index (RSI) | N/A | N/A |
| Support Level | N/A | N/A |
| Resistance Level | N/A | N/A |
| Average True Range (ATR) | 0.00 | 0.00 |
| MACD | 0.00 | 0.00 |
| Stochastic Oscillator | 0.00 | 0.00 |
The Middleby Corp is engaged in the foodservice industry. The company develops and manufactures a broad line of solutions used in commercial foodservice and food processing. The group showcases its solutions in the Middleby Innovation Kitchens for commercial foodservice and industrial baking and protein Innovation Centers for food processing solutions.
PTC Therapeutics Inc is a biopharmaceutical company that discovers, develops and commercializes clinically differentiated medicines that provide benefits to children and adults living with rare disorders. Its diversified therapeutic portfolio that includes several commercial products and product candidates in various stages of development, including discovery, research and clinical stages, focused on the development of new treatments for multiple therapeutic areas for rare diseases relating to neurology and metabolism. The company views its operations and manages its business in one operating segment: life science, which is focused on the discovery, development and commercialization of the company's clinically differentiated medicines that provide benefits to patients with rare disorders.